New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field.
- Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies
- Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed
- Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
Dateigröße
ISBN-13
978-0-12-823276-7 (9780128232767)
Schweitzer Klassifikation
1. Current status of recurrent glioblastoma therapies
2. Imaging of glioblastoma recurrence
3. Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma
4. The intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies
5. Targeting Glioma Stem Cell Metabolism to Enhance Therapy Responses and Minimize Resistance
6. Targeting Tumor Microenvironment Associated Cells to Reverse Therapy Resistance
7. Recent Progress in Immunotherapy for Glioblastoma
8. The Role of Convection Enhanced Deliver in the Treatment of GBM
9. TBA Sensitization of Resistant GBM to Radiation
